This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This KILLIN antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 136-163 amino acids from the C-terminal region of human KILLIN.
KLLN
Reactivity: Human
WB, ELISA
Host: Rabbit
Polyclonal
FITC
Application Notes
WB: 1:500
Restrictions
For Research Use only
Format
Liquid
Buffer
Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date
6 months
Wang, Roma, Nolley, Abdul-Karim, Peehl, Eng: "Nuclear KLLN expression associates with improved relapse-free survival for prostate carcinoma." in: Endocrine-related cancer, Vol. 21, Issue 4, pp. 579-86, (2014) (PubMed).
Wang, Yu, He, Romigh, Altemus, Eng: "Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation." in: Molecular cancer therapeutics, Vol. 13, Issue 2, pp. 517-27, (2014) (PubMed).
Wang, He, Yu, Eng: "Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas." in: Human molecular genetics, Vol. 22, Issue 11, pp. 2263-72, (2013) (PubMed).
Target
KLLN
(Killin, p53-Regulated DNA Replication Inhibitor (KLLN))
DNA-binding protein involved in S phase checkpoint control-coupled apoptosis by mediating TP53/p53-induced apoptosis. Has the ability to inhibit DNA synthesis and S phase arrest coupled to apoptosis. Has affinity to both double-and single-stranded DNA.